X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/08/2843312/0/en/Akero-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com//news-release/2024/03/07/2842721/0/en/Akero-Therapeutics-Announces-Publication-of-Phase-2b-SYMMETRY-Cohort-D-Study-in-Clinical-Gastroenterology-and-Hepatology.html
https://www.biospace.com/article/akero-bounces-back-in-mash-posts-positive-mid-stage-fibrosis-data/
https://www.globenewswire.com//news-release/2024/03/06/2841024/0/en/Akero-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/03/04/2839994/0/en/Akero-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/03/04/2839329/0/en/Akero-Therapeutics-Reports-Statistically-Significant-Histological-Improvements-at-Week-96-in-Phase-2b-HARMONY-Study.html
https://www.globenewswire.com//news-release/2024/02/29/2837913/0/en/Akero-Therapeutics-to-Present-Topline-Week-96-Results-from-Phase-2b-HARMONY-Study-Investigating-Efruxifermin-in-Patients-with-Pre-Cirrhotic-MASH.html
https://www.globenewswire.com//news-release/2024/02/29/2837838/0/en/Akero-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/01/03/2803286/0/en/Akero-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/18/2797681/0/en/Akero-Therapeutics-Announces-First-Patients-Dosed-in-Efruxifermin-Phase-3-SYNCHRONY-Program.html
Market Place
Share 
